Treatment of Opioid Use Disorder: Waiver Qualifying - Ann Arbor, MI - Friday, July 16, 2021

Product not yet rated

Includes a Live Event on 07/16/2021 at 8:00 AM (EDT)

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!
image

Host: Michigan Opioid Collaborative

Friday, July 16, 2021 | 8:00 am - 5:00 pm ET

Live Virtual Course 

Overview

This 8-hour live virtual course covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices and also provides the required education needed to obtain the waiver to prescribe buprenorphine.  This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

The target audience includes: Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.

The ACGME competencies include: 

Learning Objectives

Module 1

  1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
  2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
  3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
  4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
  5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

  1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
  2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
  3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

  1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
  2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
  3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Fees

Rate DescriptionRate
ASAM Member$0
Non-Member$0
Retired Member$0
Associate Member$0
Resident Member*$0
Student Member*$0

(*) Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. 

Click here to become an ASAM member.

*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the email us, or view the email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM e-Learning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

Registration Deadline: 7/16/2021

Course Instructions

  1. Click the Contents tab and select Attend Live Course.  After live course has completed, return to the Contents tab.
  2. Click Complete Post Test to answer quiz questions.  After completing the quiz, return to the Contents tab.
  3. Click Complete Evaluation to answer evaluation questions. Scroll down on all questions, there are answers that expand past the size of the window. Submit the evaluation (the next box should activate, and the evaluation box should turn green with a white check mark).
  4. Click the button “Claim Medical Credits” in the box titled “Claim Credits & Certificate." Choose the type of credit and click submit. Click the button “View/Print Certificate” to save or print your certificate. If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your transcript (found in the Dashboard).
  5. Click on the other tabs to view information on the speakers, credit and disclosures, and handouts related to the course.


Need Assistance?

If you have are experiencing any log in issues, cannot access a course, need assistance claiming credit, or have other questions or concerns, please e-mail Education@asam.org for assistance.

For learners who may have difficulty typing, moving a mouse or reading, Essential Accessibility is an application available for use to assist.

Sheba Sethi

MD

University of Michigan

Sheba Sethi, MD works as an addiction medicine consultant and primary care doctor at Packard Health. She is board certified in Internal Medicine and is a member of American Society of Addiction Medicine (ASAM). She graduated from Drexel University College of Medicine in 2016. She did her internal medicine residency training at Montefiore Medical Center Primary Care and Social Medicine program in the Bronx, NY. She is passionate about social medicine or the study of how social, economic, environmental and epidemiologic conditions impact health and disease. Her clinical interests involve treatment of substance use disorders as well as care of vulnerable populations.

Jonathan Morrow

MD, PhD

University of Michigan

Jonathan Morrow, M.D., Ph.D. received his B.S. in Biological Sciences from the University of Southern California, and his M.D. and Ph.D. in Neuroscience from the University of Michigan. Dr. Morrow went on to complete his residency training in Adult Psychiatry at the University of Michigan, and subsequently joined the faculty of the University of Michigan as an Assistant Professor of in 2011. He provides medication management and other clinical care to patients through the University of Michigan Addiction Treatment Services. His clinical interests include treatment of co-occurring psychiatric disorders such as addiction and post-traumatic stress disorder (PTSD). The Morrow lab uses behavioral, pharmacological, immunohistochemical, and neurosurgical techniques to identify and manipulate specific neural circuits that show individual differences relevant to multiple psychiatric disorders, including both addiction and PTSD.

Credits and Disclosures


ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

California Consortium of Addiction Programs and Professionals (CCAPP)

This educational program is approved by CCAPP: #OS-20-330-1222

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification


American Board of Preventive Medicine (ABPM)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

American Board of Surgery (ABS)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

CME Reviewer and Disclosure Information


ASAM CME Committee Reviewer

Benjamin Bearnot, MD - Does Disclose

• We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board 

• Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

Faculty and Planning Committee


Faculty Disclosure Information

Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures 
Mount Sinai Beth Israel, New York, NY

Marian Currens, CRNP – Does Disclose 
University of Maryland Baltimore, Baltimore, MD

  • ASAM, Consultant/Advisory Board, Clinical Condition: MedNP ED

Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures 
First Judicial District Court, Santa Fe, NM

Daniel P. Alford, MD, MPH, DFASAM - No Relevant Financial Disclosures 
Boston Medical School and Boston University School, Boston, MA

Corey Waller, MD, MS, DFASAM, FACEP – No Relevant Financial Disclosures 
Health Management Associates, Lansing, MI


Planning Committee Disclosure Information

Melissa Weimer, DO, MCR, FASAM – Does Disclose

  • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

Deanna Wilson, MD, MPH– No Relevant Financial Disclosures
Pittsburgh, PA

Alta DeRoo, MD, FASAM – Does Disclose

  • Indivior, Speaker honorarium
  • Alkermes, Speaker honorarium

Soraya Azari, MD – No Relevant Financial Disclosures
San Francisco, CA

Kristen Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
Atlanta, GA

Matt Tierney, NP, CNS – No Relevant Financial Disclosures
San Francisco, CA

Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
Santa Fe, NM

Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
New York, NY

Key:

Complete
Failed
Available
Locked
Complete Pre-Course Survey
2 Questions
2 Questions Please answer the following
Attend Live Virtual Course
07/16/2021 at 8:00 AM (EDT)   |  60 minutes
07/16/2021 at 8:00 AM (EDT)   |  60 minutes Learners may join 15 minutes prior to start time. Audio is via computer speakers/headphones. There is no option to join via telephone.
Complete Evaluation
14 Questions
14 Questions Scroll down on evaluation, there may be questions that expand past the size of the window.
Claim Credits & Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available This session has been approved for 8 AMA PRA Category 1 Credits. Participants should claim only the credits commensurate with the extent of their participation in the activity.

How to Apply for a Waiver

Physicians

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Other Approved Prescribers

Apply

NPs and PAs may upload copies of their training certificates on the Waiver Notification Form. NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
  • Complete no less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.